Exchange: NASDAQ·Updated 07:40 PM EST
PMVP logo

PMVP PMV Pharmaceuticals Inc

$0.862
$0.434
(33.13%)
Today
Closed $0.876
$0.014
(1.60%)
After Hours
Reported EarningsNov 10
Mkt Cap$66.17M
Vol4.82M

About PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
63

Bullish Sentiment

How do you feel about PMVP?

buymoremakemore
$PMVP I think we see a runup this week. Data should be validated, and that should cause a jump towards $2, since confirmed data on followup would massively derisk stock heading into pdufa next year with enough cash. The warrants shouldnt be a big issue.
4
Gurujoe
$PMVP down ~30% after ENA. The selloff looks steep to me given the rezatapopt data and the path to filing. • 48% confirmed ORR (31/65), 10.4 months median response duration and 83% disease control with once-daily oral monotherapy in TP53 Y220C platinum-resistant/refractory ovarian cancer. • Tracks closely with prior releases. The broad ovarian cohort showed 41% confirmed ORR at ENA vs. 43% at the prior cutoff. Median response duration was 10.0 months at the prior cutoff and 10.4 months in the pivotal group. Blinded central review remains the key result to watch. • Late-line context. The broader cohort had a median of four prior lines. One historical fifth-line chemo series reported ~16% response. Cross-trial context only. • Registrational package. These pivotal data support PMVP’s planned Q1 2027 NDA seeking accelerated approval. • Management’s market estimate. ~$550–700M U.S. and ~$850M–$1B globally for the broader 2L+ ovarian opportunity. PMVP estimates ~1,900 addressable patients across the U.S., UK and four major EU markets. The initial filing targets a narrower population. These figures describe market potential. Launch revenue guidance hasn’t been issued.
2
investfreakycat
$PMVP ENA 2026 Programme updates, 12LBA: Efficacy, molecular activity and safety from the pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a p53 reactivator, in TP53 Y220C-positive advanced solid tumors LATE BREAKING speaker: Alison Schram, USA
3
Biotech_Pharma_Investor
$PMVP (NP) Data seem consistent with prior data (slightly lower OR). Problems: - Limited efficacy outside gynecological ca - Toxic warrants that reset upon FDA NDA acceptance - no BICR yet Terrible market for clinical-stage small/micro/nano-caps
2
MarketMana
$PMVP Yikes. Data wasn't even bad, from what I can tell, and they have cash till 2028. Sell the news, I guess.
2
buymoremakemore
$PMVP Nothing has changed. Should make a run to $2 on NDA submission PR. Maybe even higher if accepted for accelerated approval
1
investfreakycat
$PMVP PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt will be featured in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The presentation will include updated data from all PYNNACLE trial cohorts.
1
Rayvio_News_Filter
$PMVP 🏥 PMV Pharmaceuticals, Inc. announced updated data from the Phase 2 pivotal portion of the PYNNACLE clinical trial of rezatapopt.
hbkstockislife
$PMVP At this rate 0 before data and and negative after data ..once a junk always a junk
lovestockstwits
$PMVP this has to be one of the worst stock of all time if not the worst..up like a turtle and down like a cheetah

Advertisement|Remove ads.